178 filings
Page 7 of 9
8-K
i4859dh73p28q
4 Dec 17
Departure of Directors or Certain Officers
12:00am
8-K
hd8h8236
22 Nov 17
Departure of Directors or Certain Officers
12:00am
8-K
5khq 4vc0zeymysw
26 Oct 17
Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update
12:00am
8-K
3zjeu7
11 Oct 17
Departure of Directors or Certain Officers
12:00am
8-K
75vkssd2ifq ynt
12 Sep 17
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
4qxnf 8yvx
6 Sep 17
Departure of Directors or Certain Officers
12:00am
8-K
unwizclfp
10 Aug 17
Entry into a Material Definitive Agreement
12:00am
8-K
bf31dvvcftrxs
27 Jul 17
Versartis Reports Second Quarter 2017 Financial Results
12:00am
8-K
51hz0uv99oig
1 Jun 17
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
cdeo4
27 Apr 17
Versartis Reports First Quarter 2017 Financial Results
12:00am
8-K
9zqv bvmfxd5441jd
3 Apr 17
Versartis Reports New Data on Long-Acting Somavaratan in Growth Hormone Deficiency at ENDO 2017
12:00am
8-K
hzmr1b9
23 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
i7s0qe1vni09 dn3ybq
21 Feb 17
Versartis Reports Fourth Quarter 2016 Financial Results
12:00am
8-K
eq8 6wje4j
31 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
cs1 w3j55tqq
28 Dec 16
Entry into a Material Definitive Agreement
12:00am
8-K
tkbwmxy4
29 Nov 16
Regulation FD Disclosure
12:00am
8-K
0pr7eagt4kh21lgt3
3 Nov 16
Versartis Reports Third Quarter 2016 Financial Results
12:00am
8-K
o4ec5o
14 Oct 16
Departure of Directors or Certain Officers
12:00am
8-K
7seos8ae hx
29 Sep 16
Other Events
12:00am
8-K
cieor49
26 Sep 16
Versartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2
12:00am